Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health.
Williams PM, Forbes T, P Lund S, Cole KD, He HJ, Karlovich C, Paweletz CP, Stetson D, Yee LM, Connors DE, Keating SM, Destenaves B, Cleveland MH, Lau CJ, Barrett JC, Kelloff GJ, McCormack RT. Williams PM, et al. Among authors: lau cj. JCO Precis Oncol. 2021 Jun 1;5:PO.20.00528. doi: 10.1200/PO.20.00528. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250423 Free PMC article.
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.
Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Jänne PA, Oxnard GR, Paweletz CP. Cheng ML, et al. Among authors: lau cj. JCO Precis Oncol. 2021 Feb 17;5:PO.20.00419. doi: 10.1200/PO.20.00419. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250387 Free PMC article.
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Bahcall M, Paweletz CP, Kuang Y, Taus LJ, Sim T, Kim ND, Dholakia KH, Lau CJ, Gokhale PC, Chopade PR, Hong F, Wei Z, Köhler J, Kirschmeier PT, Guo J, Guo S, Wang S, Jänne PA. Bahcall M, et al. Among authors: lau cj. Mol Cancer Ther. 2022 Feb;21(2):322-335. doi: 10.1158/1535-7163.MCT-21-0344. Epub 2021 Nov 17. Mol Cancer Ther. 2022. PMID: 34789563 Free PMC article.
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB. Rangachari D, et al. Among authors: lau cj. J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1. J Thorac Oncol. 2019. PMID: 31377341 Free PMC article.
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, Kolifrath S, Aref AR, Lau CJ, Paweletz CP, Bu X, Freeman GJ, Barrasa MI, Weinberg RA, Sharpe AH, Ploegh HL. Rashidian M, et al. Among authors: lau cj. Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16971-16980. doi: 10.1073/pnas.1905005116. Epub 2019 Aug 2. Proc Natl Acad Sci U S A. 2019. PMID: 31375632 Free PMC article.
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.
Sehgal K, Portell A, Ivanova EV, Lizotte PH, Mahadevan NR, Greene JR, Vajdi A, Gurjao C, Teceno T, Taus LJ, Thai TC, Kitajima S, Liu D, Tani T, Noureddine M, Lau CJ, Kirschmeier PT, Liu D, Giannakis M, Jenkins RW, Gokhale PC, Goldoni S, Pinzon-Ortiz M, Hastings WD, Hammerman PS, Miret JJ, Paweletz CP, Barbie DA. Sehgal K, et al. Among authors: lau cj. J Clin Invest. 2021 Jan 19;131(2):e135038. doi: 10.1172/JCI135038. J Clin Invest. 2021. PMID: 33151910 Free PMC article.
65 results